(Press-News.org) CHICAGO — Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with metastatic, castration-resistant prostate cancer, according to Charles J. Ryan, M.D., associate professor of clinical medicine and urology at University of California-San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Calif.
"We have identified that patients who have higher levels of androgen compared with those with lower levels have a better prognosis overall and a better prognosis when receiving abiraterone than patients with lower levels of androgens," said Ryan. "Patients with low hormone levels seem to have a worse prognosis overall; however, they still benefitted significantly from receiving abiraterone as opposed to receiving placebo."
In the past, this form of prostate cancer was referred to as hormone-refractory prostate cancer. However, this term is no longer used because, in recent years, researchers have discovered that certain drugs, like abiraterone, which are essentially hormone therapies, improve outcomes and survival rates.
In this prospective substudy, Ryan and colleagues evaluated data from a randomized phase III trial that compared abiraterone to placebo and led to the approval of abiraterone. They categorized patients according to high levels or low levels of hormones.
The results indicated that higher baseline hormone levels were associated with significantly higher overall survival in patients regardless of initial treatment compared with low baseline levels. Patients assigned to placebo and who had high hormone levels had nearly 50 percent improvement in survival compared with those assigned to placebo and who had low hormone levels. In addition, abiraterone was associated with longer overall survival compared with treatment with placebo in patients with high and low levels of baseline hormones.
Patients assigned to abiraterone who had high baseline levels of hormones had almost twice the overall survival compared with those with low levels of hormones assigned to placebo.
"We used to think that it was not necessary to measure hormone levels once they were below normal — that was in part due to the fact that we were using insensitive assays," Ryan said. "However, now we know that they have prognostic and predictive significance and that physicians treating these patients should think about conducting hormone tests."
According to Ryan, more work is required to determine how these data will inform the standard-of-care management of patients with prostate cancer; however, it is likely that these data will affect the design of future clinical trials.
###
The study was sponsored by Cougar Biotechnology, which is owned by Johnson & Johnson.
Press registration for the AACR Annual Meeting 2012 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration.
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR's membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for patient benefit. The AACR actively communicates with legislators and policy makers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit http://www.AACR.org.
Presenter: Charles J. Ryan, M.D.
Abstract Number: LB-434
Title: Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Results of the COU-AA-301 phase 3 randomized trial.
Author Block: Charles Ryan1, Jinhui Li2, Thian Kheoh3, Howard I. Scher4, Arturo Molina3. 1University of California-San Francisco, San Francisco, CA; 2Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ; 3Ortho Biotech Oncology Research & Development (Unit of Cougar Biotechnology), Los Angeles, CA; 4Memorial Sloan Kettering Cancer Center, New York, NY.
Objective: In COU-AA-301 the androgen biosynthesis inhibitor abiraterone acetate (AA) significantly increased OS vs placebo (PL) in mCRPC post-docetaxel (HR=0.74; Scher, ASCO 2011). The objective of the current study was to determine the effect of baseline levels of adrenal androgens (testosterone [T], androstenedione [A4], and dehydroepiandrostenedione [DHEA]) on OS in COU-AA-301.
Methods: COU-AA-301 is a randomized double blind study of AA (1000 mg QD + prednisone [P] 5 mg po BID) vs PL + P. In this post hoc exploratory analysis, the effect of baseline serum androgen levels (T, A4, DHEA) on OS was determined by univariate and multivariate analyses using the Cox proportional hazards regression model. Cut offs for high hormone (HH; above median) and low hormone (LL; below median) levels were used. Pts were stratified by ECOG PS (0-1 vs 2), pain (pain 4-10 [present] vs pain 0-3 [absent]), 1 vs 2 prior chemotherapy regimens, and type of progression (PSA only vs radiographic).
Results: Higher baseline serum androgens (T, A4, and DHEA) were associated with significantly improved OS, in either univariate or multivariate analysis, adjusting for treatment, other androgens, and other lab parameters (ie, LDH, HGB, ALKP, PSA; all p END
Baseline hormone levels may predict survival in metastatic, castration-resistant prostate cancer
2012-04-04
ELSE PRESS RELEASES FROM THIS DATE:
Young women at growing risk of drunk-driving crashes
2012-04-04
PISCATAWAY, NJ – Underage female drinkers have been at a growing risk of fatal car crashes in recent years -- so much that they've caught up with their male counterparts, according to a study in the May issue of the Journal of Studies on Alcohol and Drugs.
Back in 1996, the U.S. had a gender split when it came to underage drinkers' odds of being involved in a fatal car crash: at any given blood-alcohol level, young men had a higher risk of a fatal crash than young women did.
But by 2007, the new study found, that gender gap had closed.
The exact reasons are not clear. ...
Credible medical evidence of widespread torture in Darfur
2012-04-04
Allegations of widespread, sustained torture and other human rights violations by the Government of Sudan and Janjaweed forces against non-Arabic-speaking civilians are corroborated in a study published in this week's PLoS Medicine. In the study medical forensic experts reviewed the medical records of patients seen at a clinic in Darfur.
The authors, co-led by Alexander Tsai based at Harvard University and Mohammed Eisa based at Physicians for Human Rights, both in Cambridge, USA, conclude: "The widespread, organized, and sustained pattern of attacks documented in our ...
Increasing height and body mass index are risk factors for ovarian cancer
2012-04-04
A study in this week's PLoS Medicine suggests that increasing height and, among women who have never taken menopausal hormone therapy, increased body mass index are risk factors for developing ovarian cancer.
These findings are important as in high income countries, the average height and average body mass index of women have increased by about 1 cm and 1 kg/m2 respectively per decade. These findings suggest that if all other factors that affect ovarian cancer risk had remained constant, the increases in height and weight among women would have resulted in ovarian cancer ...
Priorities for health systems strengthening efforts from the US CDC
2012-04-04
In this week's PLoS Medicine, Peter Bloland and colleagues from the US Centers for Disease Control and Prevention (CDC) lay out the agency's priorities for health systems strengthening efforts. To guide its support of public health in low- and middle-income countries around the world, the CDC proposes to focus its investments on strengthening six key public health functions that would contribute the most towards health systems strengthening efforts as a whole and have the greatest impact on improving the public's health. These include ensuring the availability of critical ...
Scientists at Fox Chase discover link between estrogen and tobacco smoke
2012-04-04
CHICAGO, IL (April 3, 2012)––The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia.
"This research provides the link between estrogen and tobacco smoke," says study author Jing Peng, Ph.D., postdoctoral associate in the lab of Margie L. Clapper, Ph.D., also a co-author on the paper.
The ...
The World's Premier Fiberglass Working Boat - Polaris
2012-04-04
The world's first fiberglass working boat, Polaris, was built by SHING SHENG FA BOAT BUILDING CO., LTD. (SSF), one of the boat builders who's been manufacturing and customizing boats for more than 41 years. SSF is recognized as a pioneer in designing and manufacturing workboats and vessels. Their workboats are designed specifically to achieve various challenges in order to present the best. SSF has been building workboats including fishery trials, oceanographic survey ships, oil spill prevent boats, patrol working boats, river working boats, etc. And their strong working ...
New compound targets key mechanism behind lymphoma
2012-04-04
CHICAGO, IL (April 3, 2012)––Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.
"It's an exciting time to be involved in lymphoma treatment and research," says study author Mitchell Smith, M.D., Ph.D., director of Lymphoma Service at Fox Chase. "There's a new understanding of the disease, and new drugs to treat it. I am optimistic that over the next couple of years treatments will continue ...
Annual mammography with screening ultrasound may benefit women at increased risk of breast cancer
2012-04-04
CHICAGO – The addition of a screening ultrasound or magnetic resonance imaging (MRI) to annual mammography in women with an increased risk of breast cancer and dense breast tissue resulted in a higher rate of detection of incident breast cancers, according to a study in the April 4 issue of JAMA.
"Annual ultrasound screening may detect small, node-negative breast cancers that are not seen on mammography. Magnetic resonance imaging may reveal additional breast cancers missed by both mammography and ultrasound screening," according to background information in the article. ...
Changes in diagnostic coding may affect data that indicate decline in pneumonia hospitalizations
2012-04-04
CHICAGO – Although data indicate that between 2003-2009 there was a substantial decline in the U.S. in hospitalizations for pneumonia and inpatient deaths, analysis suggests that trends in documentation and diagnostic coding, rather than improvements in actual outcomes, may explain much of the observed changes, according to a study in the April 4 issue of JAMA.
Pneumonia is a leading cause of illness and death among U.S. adults, resulting in more than 1 million annual hospital admissions and accounting for more than $10.5 billion in aggregate costs. "Given its public ...
Adding drug to chemotherapy following colon cancer surgery does not improve disease-free survival
2012-04-04
CHICAGO – Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA.
Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and oxaliplatin (FOLFOX or slightly different method, FLOX) provides significant ...